 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...4445464748495051525354...100101» |
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
New P2 trial: ZYYY-BC-001: Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer (clinicaltrials.gov) - Aug 9, 2021
P2, N=40, Not yet recruiting, Sponsor: First Affiliated Hospital of Zhejiang University
- | letrozole / Generic mfg.
Preclinical, Journal: A new clinically-relevant rat model of letrozole-induced chronic nociceptive disorders. (Pubmed Central) - Aug 8, 2021
This new long-lasting chronic rat model, efficiently reproduces the symptoms of AI-induced nociceptive disorder affecting patients' daily activities and quality-of-life. It should help to study the pathophysiology of this disorder and to promote the development of new therapeutic strategies.
- | tamoxifen / Generic mfg.
Journal: Role of Persistent Organic Pollutants in Breast Cancer Progression and Identification of Estrogen Receptor Alpha Inhibitors Using In-Silico Mining and Drug-Drug Interaction Network Approaches. (Pubmed Central) - Aug 7, 2021
Based on the lowest-scoring values, ZINC08441573, ZINC00664754, ZINC00702695, ZINC00627464, and ZINC08440501 (synthetic compounds), and capsaicin, flavopiridol tectorgenin, and ellagic acid (natural compounds) showed incredible interactions with the active sites of ERα, even more convening and resilient than standard breast cancer drugs Tamoxifen, Arimidex and Letrozole. Our findings confirm the role of POPs in breast cancer progression and suggest that natural and synthetic compounds with high binding affinity could be more efficient and appropriate candidates to treat breast cancer after validation through in vitro and in vivo studies.
- | Kisqali (ribociclib) / Novartis
Clinical Trial,Phase II, Journal: Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy: ER activity in pre-menopausal HR+ breast cancer during CT. (Pubmed Central) - Aug 7, 2021
Chemotherapy reduces the expression of ER-regulated genes in pre-menopausal women suffering from hormone-dependent BC by supressing ovarian function. Further studies should test the value of chemotherapy in this patient population when ovarian function is suppressed by other methods.
- | NN1213 / Novo Nordisk
Trial completion, Trial completion date, Trial primary completion date: BARONET: Radiological and Biological Tumoural and Peri-tumoural Factors in Neoadjuvant Endocrine-treated Breast Cancers (clinicaltrials.gov) - Aug 6, 2021
P=N/A, N=31, Completed, Sponsor: NHS Tayside
Further studies should test the value of chemotherapy in this patient population when ovarian function is suppressed by other methods. Active, not recruiting --> Completed | Trial completion date: May 2022 --> Dec 2020 | Trial primary completion date: May 2020 --> Dec 2020
- || letrozole / Generic mfg., clomifene citrate / Generic mfg.
Clinical, Journal: Does ovarian stimulation benefit ovulatory women undergoing therapeutic donor insemination? (Pubmed Central) - Aug 5, 2021
Ovarian stimulation in TDI cycles resulted in a <4% increase in clinical and <1% increase in ongoing pregnancy, and more than fourfold increase in ongoing multiple gestations. Natural cycle IUI should be considered as a first-line treatment for ovulatory women who need donor insemination.
- || letrozole / Generic mfg., tamoxifen / Generic mfg.
Clinical, Journal: Effects of letrozole or tamoxifen coadministered with a standard stimulation protocol on fertility preservation among breast cancer patients. (Pubmed Central) - Aug 4, 2021
There may be a negative effect of letrozole or tamoxifen on fertilization and embryo quality, in fertility preservation cycles. Further studies are needed to confirm these findings.
- | Ibrance (palbociclib) / Pfizer
Enrollment closed, Trial completion date, Trial primary completion date: PREDIX LumB: Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases (clinicaltrials.gov) - Aug 3, 2021
P2, N=181, Active, not recruiting, Sponsor: Thomas Hatschek
Further studies are needed to confirm these findings. Recruiting --> Active, not recruiting | Trial completion date: Jun 2031 --> Dec 2031 | Trial primary completion date: Dec 2021 --> Jul 2021
- | letrozole / Generic mfg.
New P1 trial: Effect of Acupuncture Plus Governor Vessel Moxibustion Combined With Letrozole on Live Birth in Anovulatory Infertile Women With Spleen-kidney Yang Deficiency PCOS (clinicaltrials.gov) - Aug 3, 2021
P1, N=90, Not yet recruiting, Sponsor: Qiu-ping Lin
- ||||| Ibrance (palbociclib) / Pfizer
New P2 trial, Circulating tumor DNA: TRAK-ER: A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer (clinicaltrials.gov) - Aug 1, 2021
P2, N=1100, Not yet recruiting, Sponsor: Royal Marsden NHS Foundation Trust
- | letrozole / Generic mfg.
Preclinical, Journal: Luteolin alleviates polycystic ovary syndrome in rats by resolving insulin resistance and oxidative stress. (Pubmed Central) - Aug 1, 2021
Female Sprague-Dawley rats were randomly divided into four groups: sham group treated with vehicle (saline) or luteolin; letrozole and high-fat-diet-induced PCOS group treated with vehicle or luteolin (25, 50, 100 mg/kg ip)...Protein and mRNA expressions of Nrf2 and downstream genes such as Hmox1 and Nqo1 were restored by luteolin in PCOS rats. Collectively, this study demonstrated that luteolin inhibited IR by prompting PI3K/AKT signaling pathway and enhanced antioxidative response through the restoration of Nrf2 pathway.
- | letrozole / Generic mfg.
Journal, IO biomarker: Potential effect of adrenomedullin on metabolic and endocrinal dysfunctions in the experimentally induced polycystic ovary: Targeting implication of endoplasmic reticulum stress. (Pubmed Central) - Jul 30, 2021
Twenty-four female Wistar rats were allocated into three groups: control; polycystic ovary syndrome (PCOS) in which PCOS was induced by letrozole, orally in a dose of 1 mg/kg once daily for 3 weeks; and ADM group in which ADM was injected intraperitonally in a dose of 3.5/μg/twice daily for 4 weeks...PCOS group exhibited increased ER stress, suppressing of PI3K/Akt1 and PPAR-γ pathways, imbalance of sex hormonal profile, hyperglycemia, insulin resistance, dyslipidemia, increased profibrotic factors, and abnormal ovarian histopathological picture, while ADM treatment alleviated these disturbances occurring in the PCOS model. We concluded that ADM mitigated PCOS via attenuating the ER stress, in addition to activation of PI3K/Akt1 and PPAR-γ pathways, its antioxidant, anti-inflammatory, antiapoptotic, and antifibrotic properties.
- || MK-2206 / Merck (MSD)
Clinical, Journal: Diffuse optical tomography breast imaging measurements are modifiable with pre-surgical targeted and endocrine therapies among women with early stage breast cancer. (Pubmed Central) - Jul 29, 2021
We concluded that ADM mitigated PCOS via attenuating the ER stress, in addition to activation of PI3K/Akt1 and PPAR-γ pathways, its antioxidant, anti-inflammatory, antiapoptotic, and antifibrotic properties. We demonstrated that DOTBIS-derived measurements are modifiable with pre-surgical AKT inhibition and endocrine therapy, supporting further investigation of DOTBIS as a potential imaging assessment of response to neoadjuvant targeted therapies in early stage breast cancer.
- | metformin / Generic mfg.
Preclinical, Journal: Impact of erythropoietin and myoinositol versus metformin on insulin resistance in a rat model of polycystic ovary syndrome. (Pubmed Central) - Jul 28, 2021
MET and myoinositol were mostly equally effective in improving the reproductive manifestations of the disease. However, EPO was most effective in decreasing the insulin level observed in this LTZ-induced model of PCOS.
- || Kisqali (ribociclib) / Novartis
Clinical, Review, Journal: CDK4/6 inhibitor-induced colitis: a case report and review of the literature. (Pubmed Central) - Jul 28, 2021
The mechanism of injury in CDK 4/6 inhibitor-induced colitis is unknown but may be related to recruitment of inflammatory cells. Whether the development of colitis is associated with tumour response is an interesting and unanswered question.
- || tamoxifen / Generic mfg., fulvestrant / Generic mfg.
Review, Journal: Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer. (Pubmed Central) - Jul 28, 2021
The PI3K/AKT/mTOR pathway is implicated in sustaining endocrine resistance and has become the target of many new drugs for ER+ breast cancer. This article reviews the function of the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway and the various classes of PI3K pathway inhibitors that have been developed to disrupt this pathway signaling for the treatment of hormone-receptor-positive breast cancer.
- | letrozole / Generic mfg.
Journal: Prolonged use of letrozole causes morphological changes on gonads in Galea spixii. (Pubmed Central) - Jul 27, 2021
In the testes of treated males, the development of seminiferous tubules was delayed and sperm was absent. The collective findings indicate that the prolonged use of letrozole alters secondary sexual characteristics, and causes weight gain, reproductive changes, and male infertility.
- || letrozole / Generic mfg.
Clinical, Journal: Letrozole-induced frozen embryo transfer cycles are associated with a lower risk of hypertensive disorders of pregnancy among women with polycystic ovary syndrome. (Pubmed Central) - Jul 24, 2021
In women with PCOS undergoing frozen embryo transfer, letrozole use for endometrial preparation was associated with a lower risk of hypertensive disorder of pregnancy compared with artificial cycles. Our findings provided a foundation that the increased risk of hypertensive disorder of pregnancy associated with frozen embryo transfer might be mitigated by the utilization of physiological endometrial preparation protocols that lead to the development of a corpus luteum, such as a mild ovarian stimulation cycle for oligo- or anovulatory women.
- ||| letrozole / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., everolimus / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC) (clinicaltrials.gov) - Jul 23, 2021
P2, N=28, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Our findings provided a foundation that the increased risk of hypertensive disorder of pregnancy associated with frozen embryo transfer might be mitigated by the utilization of physiological endometrial preparation protocols that lead to the development of a corpus luteum, such as a mild ovarian stimulation cycle for oligo- or anovulatory women. Active, not recruiting --> Completed | N=84 --> 28 | Trial completion date: Jul 2022 --> Jul 2021 | Trial primary completion date: Jul 2022 --> Jul 2021
- || Kisqali (ribociclib) / Novartis
Enrollment closed, Trial primary completion date: NEOLBC: Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer. (clinicaltrials.gov) - Jul 23, 2021
P2, N=100, Active, not recruiting, Sponsor: Borstkanker Onderzoek Groep
Active, not recruiting --> Completed | N=84 --> 28 | Trial completion date: Jul 2022 --> Jul 2021 | Trial primary completion date: Jul 2022 --> Jul 2021 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2021 --> Dec 2021
- Ibrance (palbociclib) / Pfizer
[VIRTUAL] A phase I/II dose-escalation and expansion study of ZN-c5, an oral selective estrogen receptor degrader (SERD), as monotherapy and in combination with palbociclib in patients with advanced estrogen receptor (ER)+/HER2- breast cancer () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1918;
P1/2
Biomarkers and pharmacodynamic effects of therapy will be explored. Subject recruitment is ongoing.
- Ibrance (palbociclib) / Pfizer
[VIRTUAL] Predictors of progression-free survival in patients with metastatic breast cancer receiving palbociclib with letrozole () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1709;
PS ≥1, liver metastases or any visceral metastases were associated with a significantly shorter PFS. This suggests PS and metastatic pattern are important predictors of PFS and could be used to influence frequency of monitoring in patients with MBC receiving palbociclib.
- Ibrance (palbociclib) / Pfizer
[VIRTUAL] Treatment patterns in black and indigenous people and people of color (BIPOC) receiving palbociclib for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in a real-world setting: POLARIS study results () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1697;
P=N/A
PAL was routinely prescribed in clinical practice for BIPOC, with the majority of patients initiating PAL at the recommended 125-mg dose. PAL was well tolerated, with similar rates of dose modifications and AEs regardless of tx partner.
- Kisqali (ribociclib) / Novartis
[VIRTUAL] Serum thymidine kinase 1 activity in patients with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first-line with ribociclib (R) and letrozole (L) in the BioItaLEE trial () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1676;
P3
Baseline and dynamic TKa changes provided independent information. Lack of TKa suppression at D15, as seen in P3, may indicate enrichment for primary resistance and poor prognosis.
- Kisqali (ribociclib) / Novartis
[VIRTUAL] Efficacy and safety of ribociclib (RIB) in combination with letrozole (LET) in patients with estrogen receptor–positive advanced breast cancer (ABC): Secondary and exploratory results of phase 3b RIBECCA study () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1634;
P3
Baseline ECOG, histological grade, therapy situation and PR status might impact PFS outcome. No new safety signals were observed.
- Ibrance (palbociclib) / Pfizer
[VIRTUAL] Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1626;
The present study demonstrates that concomitant use of PPIs in mBC patients treated with palbociclib has a detrimental effect on PFS. Therefore, it is recommended to prescribe PPI with caution in these patients, or administering H2-antagonists or PPI for very short periods.
- everolimus / Generic mfg.
[VIRTUAL] BOLERO-5: A phase II study of everolimus and exemestane combination in Chinese post-menopausal women with ER+/HER2- advanced breast cancer () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1625;
P2
BOLERO-5 is a randomized, double-blind, placebo controlled, phase II trial comparing EVE (10 mg qd) or placebo (PBO) in combination with EXE (25 mg qd). The efficacy and safety of BOLERO-5 validate the findings from BOLERO-2, and further support the use of EVE + EXE in Chinese post-menopausal women with ER+, HER2- ABC.
- Ibrance (palbociclib) / Pfizer
[VIRTUAL] Real-world comparative effectiveness of palbociclib plus letrozole vs letrozole in older patients with metastatic breast cancer () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1623;
P=N/A
The efficacy and safety of BOLERO-5 validate the findings from BOLERO-2, and further support the use of EVE + EXE in Chinese post-menopausal women with ER+, HER2- ABC. This comparative analysis of PB+LE vs LE alone provides evidence of effectiveness for the palbociclib combination, supporting this treatment as a standard of care for older HR+/HER2- MBC patients in the first line setting.
- Ibrance (palbociclib) / Pfizer
[VIRTUAL] Effect of palbociclib (PAL) + endocrine therapy (ET) on time to chemotherapy (TTC) across subgroups of patients (pts) with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC): Post hoc analyses from PALOMA-2 (P2) and PALOMA-3 (P3) () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1621;
P3
Across all subgroups, PAL + ET vs PBO + ET prolonged TTC. As expected, pts in P2 who received PAL + ET in the first-line setting had a longer time to subsequent CT than pts in P3 who received PAL + ET after progressing on prior ET.
- Kisqali (ribociclib) / Novartis
[VIRTUAL] Longitudinal circulating tumor DNA (ctDNA) analysis in the phase 1b MONALEESASIA study of ribociclib (RIB) + endocrine therapy (ET) in Asian patients (pts) with hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC) () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1619;
P1
ctDNA levels were dynamic throughout treatment in Asian pts with HR+/HER2– ABC in MONALEESASIA. These findings suggest that on-treatment ctDNA levels may help identify pts at risk of progression.
- Ibrance (palbociclib) / Pfizer
[VIRTUAL] PALOMA-4: Primary results from a phase III trial of palbociclib (PAL) + letrozole (LET) vs placebo (PBO) + LET in Asian postmenopausal women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative (ER+/HER2–) advanced breast cancer (ABC) (Channel 1) - Jul 22, 2021 - Abstract #ESMO2021ESMO_1227;
P3
These findings suggest that on-treatment ctDNA levels may help identify pts at risk of progression. PALOMA-4, the largest study to date of a cyclin-dependent kinase 4/6 inhibitor in Asian pts with ABC, confirmed the efficacy and safety of PAL + LET as first-line therapy in postmenopausal Asian women with ER+/HER2– ABC.
- Kisqali (ribociclib) / Novartis
[VIRTUAL] Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB) (Channel 1) - Jul 22, 2021 - Abstract #ESMO2021ESMO_1050;
P3
After a median follow-up of >6.5 y, median OS improvement was >12 mo for 1L RIB + LET vs PBO + LET. Editorial support was funded by Novartis Pharmaceuticals Corporation.
- letrozole / Generic mfg., tamoxifen / Generic mfg.
[VIRTUAL] Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: A randomised, phase III trial of the Gruppo Italiano Mammella (Channel 5) - Jul 22, 2021 - Abstract #ESMO2021ESMO_1005;
P3
Editorial support was funded by Novartis Pharmaceuticals Corporation. In post-menopausal breast cancer patients treated with 2-3 years of tamoxifen, extended treatment with 5 years of letrozole resulted in a significant and clinically meaningful improvement in both DFS and OS compared to the duration of 2-3 years of letrozole.
- || letrozole / Generic mfg., estradiol valerate / Generic mfg.
Preclinical, Review, Journal: Recent updates on animal models for understanding the etiopathogenesis of polycystic ovarian syndrome. (Pubmed Central) - Jul 22, 2021
The review focuses on various animal models explored to understand the pathophysiology of PCOS. The article also highlights some environmental and food-related models that have been used to induce PCOS.
- | progesterone / Generic mfg., spironolactone / Generic mfg.
Preclinical, Journal: Pharmaceutical and Pharmacological Evaluation of the Effect of Nano-Formulated Spironolactone and Progesterone on Inflammation and Hormonal Levels for Managing Hirsutism Experimentally Induced in Rats. (Pubmed Central) - Jul 22, 2021
A significant reduction in hair follicle diameter and density was observed after topical application of SP or PG nano-gels. Finally, the outcomes pose a strong argument that the development of topically administered SP-NLC can be explored as a promising carrier over PG-NLC for more effectual improvement in the visible sign of hirsutism.
- || paclitaxel / Generic mfg., fulvestrant / Generic mfg.
Clinical, Journal: Health care-related time costs in patients with metastatic breast cancer. (Pubmed Central) - Jul 21, 2021
Finally, the outcomes pose a strong argument that the development of topically administered SP-NLC can be explored as a promising carrier over PG-NLC for more effectual improvement in the visible sign of hirsutism. Time spent traveling and receiving inpatient care represented a substantial burden to patients with MBC, with variation in time by treatment type and administration method.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
Enrollment open, Trial initiation date: MUKDEN 01: Pyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Stage II-III TPBC: a Phase II Trial (clinicaltrials.gov) - Jul 20, 2021
P2, N=89, Recruiting, Sponsor: Shengjing Hospital
Time spent traveling and receiving inpatient care represented a substantial burden to patients with MBC, with variation in time by treatment type and administration method. Not yet recruiting --> Recruiting | Initiation date: Sep 2020 --> Jul 2021
- || Kisqali (ribociclib) / Novartis
Trial primary completion date, Combination therapy, Metastases: Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer. (clinicaltrials.gov) - Jul 19, 2021
P2, N=327, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting | Initiation date: Sep 2020 --> Jul 2021 Trial primary completion date: Jun 2021 --> Feb 2022
- || letrozole / Generic mfg.
Clinical, Journal, HEOR: Cost-effectiveness of maintenance hormonal therapy in patients with advanced low grade serous ovarian cancer. (Pubmed Central) - Jul 18, 2021
Trial primary completion date: Jun 2021 --> Feb 2022 Maintenance letrozole is a cost-effective treatment strategy in patients with advanced LGSC resulting in clinically-relevant improvement in QALYs, LYs, and fewer disease recurrences.
- | letrozole / Generic mfg.
Preclinical, Journal: Altered vitamin D metabolism in the ovary and periovarian adipose tissue of rats with letrozole-induced PCOS. (Pubmed Central) - Jul 18, 2021
Concluding, our results provide the first evidence of disrupted VD metabolism in the ovary and POAT of PCOS rats. The reduced 1,25(OH)D concentration in those tissues suggests their contribution to VD deficiency observed in PCOS and might implicate in PCOS pathogenesis.
- ||| Ibrance (palbociclib) / Pfizer
Retrospective data, Review, Journal, Adverse events: Oral adverse effects of CDK4/6 inhibitors among breast cancer patients: a systematic review and meta-analysis. (Pubmed Central) - Jul 18, 2021
The specific quantitative impacts on patient quality of life and compliance require further questionnaire investigation. More in-depth individual-level data are needed to quantify the effect of stomatitis on patients' quality of life and treatment compliance.
- | letrozole / Generic mfg.
Journal: Mammospheres of letrozole-resistant breast cancer cells enhance breast cancer aggressiveness. (Pubmed Central) - Jul 17, 2021
To validate this finding, wound healing assays were performed, and LTLT-Ca mammospheres exhibited a 70% wound closure, whereas AC-1 mammospheres exhibited a 39% wound closure. Collectively, the present findings demonstrated a strong association between AI-resistant mammospheres and an increased propensity for migration, which may be indicative of a poor prognosis.
- | letrozole / Generic mfg.
Journal: Letrozole as an adjunct treatment in antagonist cycles that previously failed in poor responders. (Pubmed Central) - Jul 16, 2021
Collectively, the present findings demonstrated a strong association between AI-resistant mammospheres and an increased propensity for migration, which may be indicative of a poor prognosis. Adjunctive letrozole administration seems to restore an IVF cycle by improving the cycle characteristics and reducing the total gonadotrophin dosage.
- | letrozole / Generic mfg.
Preclinical, Journal: Mesenchymal stem cell therapy ameliorates metabolic dysfunction and restores fertility in a PCOS mouse model through interleukin-10. (Pubmed Central) - Jul 16, 2021
For in vivo experiment, BM-hMSC were implanted into letrozole (LTZ)-induced PCOS mouse model...Our results suggest that BM-hMSC can reverse PCOS-induced inflammation through IL-10 secretion. BM-hMSC might be a novel and robust therapeutic approach for PCOS treatment.
- |||||||||| camizestrant (AZD9833) / AstraZeneca
New P3 trial, Circulating tumor DNA: Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) (clinicaltrials.gov) - Jul 15, 2021
P3, N=302, Recruiting, Sponsor: AstraZeneca
- | letrozole / Generic mfg.
Preclinical, Journal: Effect of High-Fat Diet on the Intestinal Flora in Letrozole-Induced Polycystic Ovary Syndrome Rats. (Pubmed Central) - Jul 15, 2021
The dysbiosis was characterized by an increased Firmicutes/Bacteroidetes ratio, an expansion of Firmicutes, a contraction of Bacteroidetes, and the decreased microbial richness. Beta-diversity also showed significant differences in intestinal microflora, compared with control rats.
- || letrozole / Generic mfg., clomifene citrate / Generic mfg.
Review, Journal: Diagnosis and Management of Infertility: A Review. (Pubmed Central) - Jul 15, 2021
Approximately 1 in 8 women aged 15 to 49 years receive infertility services. Although success rates vary by age and diagnosis, accurate diagnosis and effective therapy along with shared decision-making can facilitate achievement of fertility goals in many couples treated for infertility.
- | letrozole / Generic mfg., anastrozole / Generic mfg.
Trial completion: Aromatase Inhibitor Growth Study: Letrozole vs. Anastrozole (clinicaltrials.gov) - Jul 15, 2021
P4, N=79, Completed, Sponsor: Stanford University
Although success rates vary by age and diagnosis, accurate diagnosis and effective therapy along with shared decision-making can facilitate achievement of fertility goals in many couples treated for infertility. Recruiting --> Completed
- ||| Ibrance (palbociclib) / Pfizer
Enrollment closed, HEOR, Patient reported outcomes, Metastases: PRECYCLE: Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy (clinicaltrials.gov) - Jul 14, 2021
P4, N=960, Active, not recruiting, Sponsor: Palleos Healthcare GmbH
Recruiting --> Completed Recruiting --> Active, not recruiting
- | letrozole / Generic mfg.
Journal: GnRH protective effects against amyloid β-induced cognitive decline: A potential role of the 17β estradiol. (Pubmed Central) - Jul 14, 2021
The electrophysiological analysis revealed the enhanced neuronal excitability in the CA1 region. All these data suggest that GnRH might be a promising candidate that reduces anxiety and improves memory indices in the context of Aβ neurotoxicity.